]. The case was provisionally diagnosed as dentigerous cyst. On excisional biopsy, the gross specimen exhibited a cystic structure surrounding the tooth at the cementoenamel junction [ Figure 3 ]. Histopathology exhibited hyperplastic cystic lining epithelium with connective tissue wall. The epithelium is of stratified squamous type, exhibiting irregular rete processes, nuclear hyperchromatism, pleomorphism and increased mitosis. Tumor cells are seen arising from the lining epithelium and extending into the lumen [ Figures 4 and 5] . Connective tissue wall is infiltrated with tumor cells in some areas. Mucicarmine and periodic acid-Schiff stain was negative. Lining epithelium resembling reduced enamel epithelium was present in a section. A diagnosis of squamous cell carcinoma (SCC) arising from dentigerous cyst was made.
The patient was later referred to an Oncology center. Associating the histopathological and imaging features [1, 2] a diagnosis of primary intraosseous SCC (PIOSCC) was made.
PIOSCC is defined as a "SCC arising within the jaw, having no initial connection with the oral mucosa and presumably developing from residual odontogenic epithelium or an odontogenic cyst or tumor." [2] Incidence of malignant transformation from odontogenic cysts ranges from 0.13% to 2%. [3] PIOSCC arising from odontogenic cysts other than of mutated c-KIT as compared to wild type. However, small numbers limit the interpretation of this finding.
While regorafenib has been approved as third-line therapy in advanced GIST after being compared with placebo, there is no head-to-head comparison with a proven tyrosine kinase inhibitor for regorafenib. [6] In our study, the median OS and median PFS survival with third-line treatment was 12.2 and 8 months, respectively, although multiple options were used. The declining number of patients receiving third-line therapy in comparison to second-and first-line therapy is also an indication of a real-world cohort, where direct application of trial data is not feasible.
This study is not without its inherent pitfalls. The retrospective nature and a relatively small sample size limit the scope of our analysis. The c-KIT mutation status was analyzed on archived FFPE paraffin blocks, and c-KIT mutation data were not available in nearly 50% of our patients. Platelet-derived growth factor receptor alpha mutation status results could not be added as the tests were standardized in recent years at our center.
Conclusion
GIST diagnosed and treated in the Indian subcontinent show improved outcomes. The importance of c-KIT mutation analysis in determining the prognosis and outcomes of patients with advanced GIST is emphasized.
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